Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181517 · ClinicalTrials.gov registry record · Phase 2
A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration
A Phase 2 study of Macular Degeneration, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02181517: Completed Phase 2 study of Macular Degeneration, sponsored by Allergan.
NCT02181517 is a Phase 2 study of Macular Degeneration that has completed, run by Allergan. The registered enrollment target is 25 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02181517, a Phase 2 study of Macular Degeneration, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
Primary Outcome
BCVA is measured using an eye chart and is reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved.
Conditions Studied
Interventions
- DRUG ranibizumab
- DRUG abicipar pegol
- OTHER sham procedure
Study Locations (1)
Arizona
- - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT02181517 record still lists
NCT02181517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which ranibizumab is the first listed.
NCT02181517 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT02181517 about?
NCT02181517 is a clinical study titled "A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration". This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration to establish comparability between Japanese and non-Japanese.
What is the current status of trial NCT02181517?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2014-07. Estimated completion is 2015-03.
What conditions does trial NCT02181517 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT02181517?
The interventions under investigation include: ranibizumab (DRUG), abicipar pegol (DRUG), sham procedure (OTHER).
Who is sponsoring clinical trial NCT02181517?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02181517 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02181517's enrollment target sits among peer trials
25 23rd of 26 higher than 4 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
ACTIVE NOT RECRUITING · Phase 2
-
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
COMPLETED · Phase 2
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia